DWJ 1589
Alternative Names: DWJ-1589Latest Information Update: 21 Feb 2025
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 26 Sep 2024 Preclinical trials in Unspecified in South Korea (unspecified route) prior to September 2024
- 23 Sep 2024 Daewoong Pharmaceutical plans a phase I Bioequivalence trial (In volunteers) in October 2024 (NCT06592495)